Herpes simplex virus type 1 (HSV-1) is a common human virus, best known as the causative agent of recurrent labial herpes (cold sores) [1] . The unique properties of HSV-1 have increasingly been exploited in vector design, particularly for therapy of the central nervous system diseases.
HSV has natural properties useful for a therapy vector: the latent, life-long infections in the nervous system with long-term gene expression, the episomal non-integrating DNA genome and the numerous dispensable genes allowing cloning of large transgenes and their regulatory sequences [2] . Numerous clinical phase I-III studies using HSV vectors are in progress on therapy of gliomas and other malignancies and of other, mainly neurological, disorders, including pain [3, 4] . 
